Garden State Investment Advisory Services LLC Makes New $253,000 Investment in Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

Garden State Investment Advisory Services LLC purchased a new stake in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 17,600 shares of the company’s stock, valued at approximately $253,000. Garden State Investment Advisory Services LLC owned about 0.13% of Greenwich LifeSciences as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Greenwich LifeSciences by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after buying an additional 1,420 shares during the period. State Street Corp raised its position in shares of Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after acquiring an additional 3,005 shares during the last quarter. Geode Capital Management LLC raised its holdings in Greenwich LifeSciences by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after purchasing an additional 5,861 shares during the last quarter. Barclays PLC lifted its holdings in Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after buying an additional 6,538 shares during the period. Finally, Rhumbline Advisers acquired a new position in shares of Greenwich LifeSciences in the 2nd quarter valued at about $117,000. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Trading Up 2.3 %

GLSI opened at $13.51 on Friday. Greenwich LifeSciences, Inc. has a 1-year low of $8.00 and a 1-year high of $21.44. The company has a market cap of $177.59 million, a price-to-earnings ratio of -16.89 and a beta of 1.61. The company’s fifty day moving average price is $13.66 and its two-hundred day moving average price is $14.45.

Wall Street Analyst Weigh In

Separately, HC Wainwright boosted their target price on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, August 23rd.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.